Headed Up or Down? Pharma's Position in the Current Economy - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Headed Up or Down? Pharma's Position in the Current Economy
Results from our annual employment survey.


Pharmaceutical Technology
Volume 33, Issue 12, pp. 30-33

Essential skills, education, training, and knowledge


Figure 10: Respondents job preference.
Respondents with bachelor s and master s degrees are approximately equal in number and each represent about one-third of respondents. At 28.9%, slightly fewer respondents hold doctorates, and a small percentage (4.5%) hold an associate's degree. The most common training was in pharmaceutics or pharmacy, representing 17% of respondents. This was followed by analytical chemistry (14.6%), and fields unrelated to pharmaceutics or science (11%). Over half of respondents were trained in the US (including Puerto Rico), followed by 12.7% trained in the UK, and almost 4% trained in India.


Figure 11: Respondents salary by region.
About one-third of respondents felt their education prepared them extremely well for their current positions, with an additional half feeling their education to have been adequate. Six percent felt their education prepared them poorly for their current positions. In contrast, almost 97% of respondents felt their previous employment experiences prepared them for their current positions.


Figure 12: Attractive job features.
Among the types of knowledge that respondents rate as important in fulfilling their functions, good manufacturing practices (GMPs) came in highest, at 86%. Next in importance is process validation (74%), followed by the US Food and Drug Administration's quality-by-design initiatives (65.8%). Skills that respondents ranked as most important were computer-based systems, including database management (77.8%), chemistry (69.2%), and automation (52.3%). Least important were aseptic processing and isolation technology (40.4%) and biotechnology (46%).


Figure 13: Job seekers least important considerations.
Among regulatory guidelines, respondents are most aware of 21 CFR Part 11, FDA's Rule on Electronic Records and Signatures (91.5%), follwed by 89% who are aware of FDA's "Pharmaceutical CGMPs for the 21st Century." Finally, 80% are aware of FDA's process analytical technology (PAT) guidance for industry. Respondents also report that these regulatory initiatives have changed the manner in which they perform their daily activities at their present jobs in the same order: 21 CFR Part 11 (50.8%), CGMPs (48.4%), and PAT (28%).


Figure 14: Respondents expected job security based on field.


Figure 15: Respondents likelihood of changing jobs this year.


Figure 16: Respondents attitude about feeling valued by employer.


Figure 17: Respondents expectations for future innovation.


Respondents


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
20%
To all process for new products only
13%
To select process for new products only
25%
To select processes for both new and legacy products
20%
Do not use QbD
23%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
Overcoming the Challenges in Biopharmaceutical Stability Testing
PhRMA Dismayed by Special 301 Report
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here